Differences Between Polycythemia Vera and Essential Thrombocythemia

November 16th 2024

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in patients with squamous non–small cell lung cancer.

Jonah Feldman

FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Campbell Surveys Participants on Favorable-Risk Frontline Approach in RCC

The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly diagnosed Ph-positive CP- and AP-CML, or for those resistant or intolerant to prior therapy, including imatinib.

SELECT-MDS-1 Trial of Tamibarotene Misses Primary End Point in MDS

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old patient with lung-metastatic renal cell carcinoma.

Balancing Clinical Data and Real-World Insights in CML Treatment

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for high-risk myelodysplastic syndrome, leading to the trial being discontinued.

Forde Discusses AE Management With Dual Checkpoint Inhibition Plus Chemotherapy in NSCLC

In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid leukemia treatment.

Related Content

November 16th 2024

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in patients with squamous non–small cell lung cancer.

Jonah Feldman

FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Campbell Surveys Participants on Favorable-Risk Frontline Approach in RCC

SELECT-MDS-1 Trial of Tamibarotene Misses Primary End Point in MDS

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old patient with lung-metastatic renal cell carcinoma.

Balancing Clinical Data and Real-World Insights in CML Treatment

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for high-risk myelodysplastic syndrome, leading to the trial being discontinued.